Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Globus Medical, Inc.'s stock has surged due to a successful execution of the NuVasive deal and three consecutive guidance hikes, boosting investor confidence and valuation. The $3.1 billion ...

The stock carries a Zacks Rank #2 (Buy) currently. Globus Medical merged its business with NuVasive. The combined company has formed a global musculoskeletal company focused on rapid innovation ...

Globus Medical and NuVasive's merger marked its first year on Sept. 1, Globus' CEO Dan Scavilla said in a Nov. 5 earnings call.

This beat is partly attributed to the early realization of some of the anticipated $170 million in cost synergies following the integration of NuVasive—a process that has been managed more ...

This beat is partly attributed to the early realization of some of the anticipated $170 million in cost synergies following the integration of NuVasive—a process that has been managed more effectively ...

The medical device maker reported big growth in revenue and earnings, driven by strong product sales and a recent major ...

Comprehensive SWOT analysis of Globus Medical Inc, highlighting key strengths, weaknesses, opportunities, and threats.

More than 200,000 Medicare patients with back pain underwent $2 billion worth of unnecessary surgeries, including spinal fusion and/or laminectomy or vertebroplasty, over a recent 3-year period, ...